Pancreatic cancer is the fourth leading cause of cancer death in the United States, with a 5-year survival rate of only 5%. Current therapies have proven ineffective, making the identification of new drug targets essential. A recently identified cellular target is the oncogenic small GTPase Rac1, which is known to sustain cell growth and invasion. Interestingly, a guanine nucleotide exchange factor (GEF) and activator of the Rac oncogene, termed Vav1, is a member of a broad class of Rac GEFs that has recently been shown to be ectopically expressed in pancreatic cancers. Although Vav1 expression is normally restricted to hematopoietic cells, its expression in pancreatic cancer has been shown to correlate with increased mortality in patients and promote increased transformation in culture and tumorigenesis in mice. The drug azathioprine is a well-established anti-inflammatory agent that has recently been shown to inhibit Vav1-Rac activity in hematopoietic cells. Our preliminary data indicate that this drug also attenuates growth of pancreatic cancer cells and markedly prevents their invasive potential in culture. Therefore, the CENTRAL HYPOTHESIS of this proposal predicts that azathioprine targets ectopically expressed VAV1 in pancreatic cancers to reduce invasive properties in vitro and metastasis in vivo. The research proposed in this pilot study will define the drug-sensitive cellular processes in pancreatic cancer cells that support metastasis, such as cell proliferation, invasive matrix degradation, and cell migration, both in cell culture (SA#1) and in nude mouse models (SA#2). The ectopic expression of this protein in a majority of pancreatic tumors makes this therapeutic approach particularly attractive. The information gathered from this proposal will provide the basis of an exciting, important, and novel pre-clinical trial toward treating this lethal disease.

Public Health Relevance

Pancreatic cancer is the fourth leading cause of cancer death in the United States, with a 5-year survival rate of only 5%. Current therapies are generally ineffective against pancreatic cancer;therefore, new therapeutic approaches are critically needed. The research described in this proposal will determine if a well-established anti-inflammatory drug could be a potential therapy for pancreatic cancers by testing its effects in pancreatic cancer cells and in mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA155778-02
Application #
8298132
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Forry, Suzanne L
Project Start
2011-07-06
Project End
2013-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$78,850
Indirect Cost
$28,850
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905